Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis, N Engl J Med, issue.22, pp.3331437-3331480, 1995. ,
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures, The Lancet, vol.348, issue.9041, pp.1535-1576, 1996. ,
DOI : 10.1016/S0140-6736(96)07088-2
Diagnosis and management of osteoporosis in postmenopausal women: Clinical guidelines, Clinical Therapeutics, vol.21, issue.6, pp.1025-1069, 1999. ,
DOI : 10.1016/S0149-2918(99)80022-8
An integrated approach: bisphosphonate management for the treatment of osteoporosis, Am J Manag Care, vol.13, issue.S11, pp.290-308, 2007. ,
El Hasnaoui A: Characterisation of patients with postmenopausal osteoporosis in French primary healthcare, Drugs Aging, issue.7, pp.24603-24617, 2007. ,
An Update on the Diagnosis and Assessment of Osteoporosis with Densitometry, Osteoporosis International, vol.11, issue.3, pp.192-202, 2000. ,
DOI : 10.1007/s001980050281
Prevalence and features of osteoporosis in the French general population: The Instant study, Joint Bone Spine, vol.76, issue.4, pp.394-400, 2009. ,
DOI : 10.1016/j.jbspin.2008.10.008
Compliance and persistence with osteoporosis therapies, Current Rheumatology Reports, vol.100, issue.Suppl2, pp.118-140, 2008. ,
DOI : 10.1007/s11926-008-0021-x
The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: A comparison of studies in the United States, the United Kingdom, and France, Clinical Therapeutics, vol.28, issue.10, pp.281686-94, 2006. ,
DOI : 10.1016/j.clinthera.2006.10.013
Adherence to treatment of osteoporosis: a need for study, Osteoporosis International, vol.39, issue.suppl, pp.181311-181328, 2007. ,
DOI : 10.1007/s00198-007-0410-4
Medication Compliance and Persistence: Terminology and Definitions, Value in Health, vol.11, issue.1, pp.44-47, 2008. ,
DOI : 10.1111/j.1524-4733.2007.00213.x
The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature, Health Economics, vol.283, issue.7, pp.601-616, 2001. ,
DOI : 10.1002/hec.609
Methods for Integrating Medication Compliance and Persistence in Pharmacoeconomic Evaluations, Value in Health, vol.10, issue.6, pp.498-509, 2007. ,
DOI : 10.1111/j.1524-4733.2007.00205.x
A Markov Model Simulation of the Impact of Treatment Persistence in Postmenopausal Osteoporosis, Medical Decision Making, vol.29, issue.1, pp.125-164, 2009. ,
DOI : 10.1177/0272989X08318461
A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis, Current Medical Research and Opinion, vol.23, issue.3, pp.585-94, 2007. ,
DOI : 10.1185/030079906X167615
Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study, Current Medical Research and Opinion, vol.22, issue.9, pp.1757-64, 2006. ,
DOI : 10.1185/030079906X132370
Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: A retrospective case???control analysis, Clinical Therapeutics, vol.30, issue.12, pp.302410-2422, 2008. ,
DOI : 10.1016/j.clinthera.2008.12.019
The impact of compliance with osteoporosis therapy on fracture rates in actual practice, Osteoporosis International, vol.45, issue.12, pp.1003-1011, 2004. ,
DOI : 10.1007/s00198-004-1652-z
Epidemiology and outcomes of osteoporotic fractures, The Lancet, vol.359, issue.9319, pp.1761-1768, 2002. ,
DOI : 10.1016/S0140-6736(02)08657-9
A model of the public health impact of improved treatment persistence in post-menopausal osteoporosis in France, Joint Bone Spine, vol.75, issue.2, pp.75201-75209, 2008. ,
DOI : 10.1016/j.jbspin.2007.06.004
Patients with Prior Fractures Have an Increased Risk of Future Fractures: A Summary of the Literature and Statistical Synthesis, Journal of Bone and Mineral Research, vol.318, issue.Suppl 5, pp.721-760, 2000. ,
DOI : 10.1359/jbmr.2000.15.4.721
Treatment of established osteoporosis: a systematic review and cost-utility analysis, Health Technology Assessment, vol.6, issue.29, pp.1-146, 2002. ,
DOI : 10.3310/hta6290
Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal, Bone, vol.33, issue.3, pp.301-308, 2003. ,
DOI : 10.1016/S8756-3282(03)00112-1
El Hasnaoui A: Comparaison of the persistance of daily and weekly bisphosphonates in Cotté and De Pouvourville BMC Health Services Research, pp.1472-6963, 2011. ,
Mortality Associated with Vertebral Deformity in Men and Women: Results from the European Prospective Osteoporosis Study (EPOS), Osteoporosis International, vol.8, issue.3, pp.291-298, 1998. ,
DOI : 10.1007/s001980050067
Mortality After Low-Energy Fractures in Patients Aged at Least 45 Years Old, Journal of Orthopaedic Trauma, vol.19, issue.6, pp.396-400, 2005. ,
DOI : 10.1097/01.bot.0000155311.04886.7e
Estimation of direct unit costs associated with non-vertebral osteoporotic fractures in five European countries, Rheumatology International, vol.115, issue.8, pp.1063-72, 2006. ,
DOI : 10.1007/s00296-006-0180-x
National Osteoporosis Guideline Group: Case finding for the management of osteoporosis with FRAX?assessment and intervention thresholds for the UK, Osteoporos Int, issue.10, pp.191395-408, 2008. ,
Drug Insight: bisphosphonates for postmenopausal osteoporosis, Nature Clinical Practice Endocrinology & Metabolism, vol.20, issue.4, pp.211-220, 2006. ,
DOI : 10.1038/ncpendmet0121
Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150???mg and risedronate 150???mg, Current Medical Research and Opinion, vol.25, issue.12, pp.2951-60, 2009. ,
DOI : 10.1185/03007990903361307
Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis, Osteoporosis International, vol.23, issue.1, pp.145-55, 2010. ,
DOI : 10.1007/s00198-009-0930-1
Validation of the adherence evaluation of osteoporosis treatment (ADEOS) questionnaire for osteoporotic post-menopausal women, Osteoporosis International, vol.54, issue.2, 2011. ,
DOI : 10.1007/s00198-011-1555-8
Patient preferences for oral versus intravenous palliative chemotherapy., Journal of Clinical Oncology, vol.15, issue.1, pp.110-115, 1997. ,
DOI : 10.1200/JCO.1997.15.1.110
Non-compliance with medication regimens and subsequent hospitalization: A literature analysis and cost of hospitalization estimate, J Res Pharm Econ, vol.2, pp.19-33, 1990. ,
Noncompliance: a $100 billion problem, Remington Report, vol.5, pp.14-19, 1997. ,
Variations in Patients??? Adherence to Medical Recommendations, Medical Care, vol.42, issue.3, pp.200-209, 2004. ,
DOI : 10.1097/01.mlr.0000114908.90348.f9
Prevalence and cost of medication nonadherence in Parkinson's disease: Evidence from administrative claims data, Movement Disorders, vol.20, issue.Suppl 1, pp.474-80, 2010. ,
DOI : 10.1002/mds.22999
Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population, Epilepsia, vol.11, issue.7, pp.446-54, 2008. ,
DOI : 10.1111/j.1528-1167.2007.01414.x
The Economic Implications of Non-Adherence after Renal Transplantation, PharmacoEconomics, vol.21, issue.6, pp.1217-1251, 2004. ,
DOI : 10.2165/00019053-200422180-00006
Clinical and Economic Outcomes of Nonadherence to Highly Active Antiretroviral Therapy in Patients With Human Immunodeficiency Virus, Medical Care, vol.44, issue.10, pp.44893-44902, 2006. ,
DOI : 10.1097/01.mlr.0000233679.20898.e9
The Clinical and Economic Burden of Nonadherence with Antihypertensive and Lipid-Lowering Therapy in Hypertensive Patients, Value in Health, vol.12, issue.4, pp.489-97, 2009. ,
DOI : 10.1111/j.1524-4733.2008.00447.x
A Pharmacoeconomic analysis of compliance gains on antipsychotic medications, Applied Health Economics and Health Policy, vol.108, issue.6, pp.189-97, 2008. ,
DOI : 10.1007/BF03256133
Evaluation of the efficacy and cost effectiveness of health education methods to increase medication adherence among adults with asthma., American Journal of Public Health, vol.80, issue.12 ,
DOI : 10.2105/AJPH.80.12.1519
Patient education and compliance: how to make it costeffective? Value Health, pp.212-217, 1998. ,